KLK3 and prostate carcinoma: Recently, a U.S.A.-based diagnostics company utilized exRNA as a predictive marker for prostate cancer, and developed a urine exosome gene expression assay to identify higher-grade prostate cancer among patients with elevated PSA levels[50,58].